O 1 P E 4200 S

Attorney Docket: 26352U

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Art Unit: 1638

TSUKAYA, et al. Examiner: Unknown

Appl. No.: 10/548, 10/507106

Filed: September 10, 2004

Title: GENE PARTICIPATING IN THE SYNTHESIS OF BRASSINOSTEROID

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- [XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [ ] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- [ ] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
  - [ ] Certification report(e) below; and
  - [ ] a check in the amount as required by 1.17(p).

Appl. No.: 10/507,106 Attorney Docket: 26352U Page 2

[ ] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

- [ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
  - I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

- [ ] Appropriate certification is attached.
- [XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- [XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

<u>or</u>

[ ] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

Appl. No.: 10/507,106 Attorney Docket: 26352U Page 3

## and / or

[ ] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

Examiner respectfully requested to cite is documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Date: November 27, 2005

.7

Respectfully submitted, NATH & ASSOCIATES PLLC

, // \

By:

iviana Amzel, Reg. No. 30,930

Customer No. 20529

NATH & ASSOCIATES PLLC 1030 15th St., N.W., 6th Fl. Washington, D.C. 20005 VA/LE (IDS.STATEMENT) Nov 2 3 2005

Attorney Docket: 26352U

IN THE A					oplifation of: Art Unit: 1638			
	FORM PTO-1449				on No:	Filed:	Examiner:	
INFORMATION DISCLOSURE CITATION					• ————	September 10, 2004	Unknown	
	<del></del>			S. PATENT D	OCUMENT	S		
Examiner Initial		Document Number		Publication Date		Inventor	Filed	
	A1							
	A2							
	А3							
	A4							
	-			EIGN PATENT	DOCUMEN			
	<del>  _  </del>	Document Number	Public	cation Date		Country	Translation	
	A5		<del> </del>					
	A6						·	
	A7							
	A8							
	A9							
	A10							
	A11							
	A12							
		OTHER (Includi	ng Autho	or, Title, [	Date, Pe	ertinent Pages, etc.)		
	A13	overexpression	XP-002967779: Kim, G, et al., "Changes in the shapes of leaves and flowers upon overexpression of cytochrome P450 in Arabidopsis", Proc. Natl. Acad. Sci. USA, vol. 96, pages 9433-9437, (1999).					
	A14	encodes a new regulated polar	XP-002967780: Kim, G, et al., "The ROTUNDIFOLIA3 gene of Arabidopsis thaliana encodes a new member of the cytochrome P-450 family that is required for the regulated polar elongation of leaf cells", Genes & Development, vol. 12, pages 2381-2391, (1998).					
	A15	CYP90, a Cytoc	XP-002036941: Szekeres, M, et al., "Brassinosteroids Rescue the Deficiency of CYP90, a Cytochrome P450, Controlling Cell Elongation and De-etiolation in Arabidopsis", Cell, vol. 85, pages 171-182, (1996).					
	A16							
Examiner					Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to